Vedolizumab SC

Takeda is running Phase 3 trial NCT06100289 to support a pediatric label for vedolizumab in moderately-to-severely active ulcerative colitis (UC) and Crohn's disease (CD), with the primary endpoint focused on steady-state pharmacokinetics in roughly ages 2-17 [1]. The adult franchise (Entyvio, IV and SC formulations) is Takeda's biggest growth driver, generating approximately ¥736 billion (~$5.1B USD) in fiscal 2024 [2], and a pediatric label fills the last major hole in the global IBD positioning. This isn't a binary efficacy readout; it's a PK bridging study with regulatory upside.

Vedolizumab IV (Entyvio) won FDA approval in May 2014 for adult UC and CD after the GEMINI program [3]. The subcutaneous pen formulation reached US approval in September 2023 for UC maintenance and April 2024 for CD maintenance, following EU approval in 2020. Takeda has been pushing the SC version hard because it shifts patients from infusion centers to self-administration, locks in adherence, and defends against the wave of oral IBD competitors. NCT06100289 is a Phase 3 pediatric trial recruiting children and teenagers with moderately-to-severely active UC or CD; the primary endpoint is steady-state trough plasma concentration at Week 34 [1]. The pediatric program is designed to support labels for both IV and SC administration: IV is typically the loading/initial route in pediatrics given dose flexibility, with SC maintenance bridged on PK exposure equivalence - the same regulatory logic Takeda used for the adult SC label. The supplemental BLA (a regulatory filing to add a new indication, in this case pediatric, to an already-approved drug) will rely on PK bridging plus safety. No special FDA designation, which is normal for label expansion of an approved biologic into pediatrics. The trial fills a pediatric gap Takeda needs covered before payers and prescribers fully shift to risankizumab and upadacitinib in pediatric IBD. Expected readout is sometime in 2027 based on current enrollment pace at the 70-patient target. Prior pediatric exposure data - open-label PK work and real-world cohorts in children - has consistently shown that weight-based or BSA-adjusted dosing produces adult-comparable exposures, which is the basis for the n=70 design.

Vedolizumab is a humanized IgG1 antibody that binds α4β7 integrin, a receptor on the surface of memory T cells. Think of α4β7 as a homing badge that lets T cells dock onto MAdCAM-1, a protein expressed almost exclusively on blood vessels in the gut [4]. Block that handshake and inflammatory T cells can't get into the intestinal wall. The result is gut-selective immunosuppression: you're not turning down the whole immune system, just the traffic into the bowel. This is what separates vedolizumab from natalizumab (Tysabri), which blocks α4β1 too and also keeps T cells out of the brain, hence Tysabri's risk of PML (progressive multifocal leukoencephalopathy, a rare and often fatal brain infection caused by JC virus reactivation) and vedolizumab's clean CNS safety record. The biology is about as validated as you get in IBD: MAdCAM-1 knockout mice resist experimental colitis, and over a decade of GEMINI program data plus real-world evidence shows consistent benefit. Vedolizumab works better in UC than CD, and the reason is anatomic: UC is a mucosal disease confined to the colonic lining, where α4β7/MAdCAM-1-mediated T cell entry dominates; CD is transmural (full-thickness) with deeper inflammatory infiltrates and additional non-α4β7 trafficking pathways, so a gut-selective surface blockade leaves more disease activity untouched. Response rates lag JAK inhibitors and IL-23 antibodies but the safety profile holds up in older or comorbid patients [5]. The gut-selective mechanism is the franchise's moat and its limit.

NCT06100289 is a Phase 3 PK/efficacy study in pediatric patients with moderately-to-severely active UC or CD [1]. Enrollment target is small at n=70; this is a bridging study, not a powered head-to-head. The primary endpoint is Ctrough,ss (steady-state trough plasma concentration) at Week 34, with secondary endpoints covering clinical remission, mucosal healing, and safety. The design is conservative and standard for pediatric label expansion: demonstrate exposure-response consistency with adults, show acceptable safety in kids, file the supplemental BLA. No comparator arm; all participants receive vedolizumab. The trial is currently recruiting. The risk in this kind of study isn't usually efficacy or even safety; it's enrollment pace. Pediatric IBD is uncommon, and parents are increasingly steered toward oral options like upadacitinib or biologics with longer-established pediatric labels such as infliximab and adalimumab. Seventy patients spanning both UC and CD across multiple international sites is going to take time. Worth noting: Takeda is also running NCT06227910, a Phase 3 combination study of vedolizumab plus upadacitinib in adult CD [6], which suggests they're not fighting the JAK wave but quietly trying to co-opt it.

Our model gives this drug a 54% chance of eventually being approved. That figure starts from the historical approval rate for Phase 3 drugs in this area - about 61% - then adjusts based on ten specific facts about the trial and its sponsor. The estimate gets a small boost from the trial's non-randomized design and open-label setup, but is pulled down by weaker earlier-phase results and smaller-than-typical enrollment. The remaining factors are close to average for this stage, so they leave the number roughly where it started.

Efficacy risk is mechanism-level: vedolizumab works through gut-selective T cell trafficking blockade, which is slower onset and less potent than systemic immunosuppression. In adult comparisons, risankizumab (IL-23 inhibitor) and upadacitinib (JAK inhibitor) consistently beat vedolizumab on endoscopic remission, particularly in CD [5]. AbbVie is running a head-to-head trial, NCT06880744, designed to compare risankizumab to vedolizumab in moderate-to-severe UC [7]; if that readout goes AbbVie's way, the franchise faces real pricing and positioning pressure. Safety risk is minimal. Vedolizumab has the cleanest profile in advanced IBD biologics, with no PML signal in over a decade of use. Pediatric-specific concerns are growth, infection, and immunogenicity, none of which have been red flags in adult or limited prior pediatric data. Commercial risk is the real story. Even with a pediatric label, US payers are increasingly fast-following ACG (American College of Gastroenterology) and AGA (American Gastroenterological Association) guideline updates that favor IL-23 inhibitors and JAKs as first-line in moderate-to-severe disease. Execution risk on this specific trial is enrollment at n=70 across rare indications in children. The bigger franchise risk is biosimilars: vedolizumab's key US composition-of-matter and method-of-use patents (Orange Book / Purple Book listings on Entyvio) are estimated to expire in the 2028-2032 window, with the SC formulation and pen-device patents extending the effective monopoly somewhat further; that staggered expiry is why the SC formulation push and pediatric label both matter strategically. Multiple biosimilar developers (including Celltrion, Alvotech, and Polpharma) have publicly disclosed early-stage vedolizumab biosimilar programs.

Watch this for what it tells you about Takeda's franchise defense strategy, not for a binary readout. The pediatric label expansion is a checkbox; it almost certainly happens, the question is timing. The real signal is whether Takeda accelerates SC penetration ahead of the AbbVie head-to-head readout. Entyvio at ~$5.1B is roughly 17% of Takeda's total revenue [2] and the single largest piece of post-Shire growth. Loss of share to risankizumab or upadacitinib over the next 36 months is the real story; the pediatric trial is defensive. Check back when NCT06880744 - AbbVie's direct head-to-head of risankizumab vs. vedolizumab in moderate-to-severe UC - produces interim or topline data [7]; based on the registered design, primary completion is estimated in 2027, with topline likely 2027-2028. That's the readout that moves Takeda's stock and rewrites IBD prescribing patterns. If risankizumab wins clearly on endoscopic endpoints, vedolizumab becomes a second-line drug. If it doesn't win on the safety-adjusted composite, vedolizumab holds market position thanks to its tolerability advantage in older and comorbid patients. The pediatric trial is noise relative to that. Worth a passing note in coverage models, not an active position.